MCRPC
Clinical trials for MCRPC explained in plain language.
Never miss a new study
Get alerted when new MCRPC trials appear
Sign up with your email to follow new studies for MCRPC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy shows promise in slowing advanced prostate cancer
Disease control OngoingThis study tests whether adding the drug talazoparib to standard treatment (enzalutamide) can slow the growth of metastatic castration-resistant prostate cancer (mCRPC). Over 1,000 men with this advanced cancer are participating. The goal is to see if the combination helps delay …
Matched conditions: MCRPC
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New antibody cocktail targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-stage trial tests whether combining two lab-made antibodies can help control metastatic castration-resistant prostate cancer (mCRPC), a tough-to-treat form of prostate cancer. Seven men with advanced disease will receive the drug combo and be monitored for side effects…
Matched conditions: MCRPC
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
Promising prostate cancer drug extended to patients already improving
Disease control ENROLLING_BY_INVITATIONThis study gives men with metastatic castration-resistant prostate cancer (mCRPC) continued access to the experimental drug ZEN003694 if they are already benefiting from it in an earlier trial. About 40 participants will receive the drug for up to two more weeks after their previ…
Matched conditions: MCRPC
Phase: PHASE1, PHASE2 • Sponsor: Zenith Epigenetics • Aim: Disease control
Last updated May 14, 2026 12:06 UTC